shutterstock_690219232
Katherine Welles / Shutterstock.com
11 June 2019Americas

Merck strengthens immunotherapy expertise with $773m buy

US-based  Merck & Co has announced plans to buy  Tilos Therapeutics, its latest acquisition in the immunotherapy space.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Americas
26 February 2019   US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

More on this story

Americas
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Americas
26 February 2019   US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

More on this story

Americas
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Americas
26 February 2019   US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.